marked.bio

Company

InxMed

4 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ifebemtinib 4garsorasib 2furmonertinib 1

Trials

4 of 4 trials shown

  1. A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

    Recruiting Phase 3 InxMed Started 2025Primary completion 2028-09 NCT07174908

    ifebemtinibgarsorasibpemetrexed

    Has KRAS G12C mutation confirmed by central laboratory

    KRAS G12CNon-Small Cell Lung Cancer

  2. IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1/2 InxMed Started 2026Primary completion 2031-02 NCT07441174

    ifebemtinib

    Subjects confirmed to be KRASG12D mutation-positive in tumor tissue samples.

    KRAS G12DSolid Tumor Cancer, PDAC

  3. IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

    Recruiting Phase 1/2 InxMed Started 2023Primary completion 2026-07 NCT05994131

    ifebemtinibfurmonertinib

    Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R.

    EGFR exon 19 deletion / L858RNSCLC

  4. a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

    Active, not recruiting Phase 1/2 InxMed Started 2022Primary completion 2027-12 NCT06166836

    garsorasibifebemtinib

    Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…

    KRAS G12CSolid Tumor